Concord Biotech Limited has informed the Exchange about Concord Biotech limited receives Establishment Inspection Report (EIR) for it''s API facility at Dholka

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹1824.90

prior close

₹1775.40

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.8%-3.5% vs market

Pharmaceuticals peers, median of 151sector+0.4%-3.1% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Smallcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+0.0

15m

+0.2

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7+0.8-3.5+0.4-3.1

Next day

-0.6+2.4-3.0+1.7-2.3

-1.4+2.7-4.0+1.3-2.7

+0.1+3.5-3.4+1.8-1.7

+0.8+4.4-3.6+3.0-2.2

-1.7+4.2-5.9+2.8-4.5

-4.3+4.2-8.4+3.4-7.6

15d

+1.4+5.3-3.9+4.8-3.4

+5.8+4.0+1.7+3.6+2.1

-4.9+0.1-5.0-1.1-3.8

-10.6+0.7-11.3+0.8-11.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech has received the Establishment Inspection Report (EIR) from the US FDA for its API manufacturing facility at Dholka, Gujarat. The USFDA had inspected this facility from April 28, 2025 to May 2, 2025. The inspection has been officially closed under 21 CFR 20.64(d)(3), meaning the USFDA found no issues requiring regulatory action. The facility is free to continue its operations without any restrictions, which is a positive outcome for the company.

Likely market impact

This is a positive development for shareholders as a clean USFDA inspection allows Concord Biotech to continue supplying APIs to the US market without disruption. It removes regulatory uncertainty around the Dholka facility and supports the company's export-driven business.